If you wear glasses or contact lances, then it is recommended that you go for an eye exam at least once a year. If you are experiencing discomfort, redness, grittiness, burning, and itching coupled with fluctuating vision, you need to rush to your eye specialist, as it could be Dry eye syndrome that may result in reduced vision and blindness.
Dry eye syndrome—clinically known as keratoconjunctivitis sicca occurs when there is decline in the amount or quality of tear composition that keep the eye wet all the time. It affects millions of people worldwide.
In order to test efficiency and safety of drug RGN-259 in the treatment of moderate to severe dry eye syndrome, RegeneRx Biopharmaceuticals, Inc. has announced that the first patient has been screened and is being enrolled in a Phase 2 clinical trial of the RGN-259 drug. The compay is expecting to enroll a total of 20 patients over the next several months. This clinical trial is being conducted under a physician-sponsored IND in Detroit, Michigan.
This study is conducted under well-known ophthalmologist and corneal specialist, Steven Dunn, who earlier treated a group of patients with recalcitrant neurotrophic keratitis with RGN-259. The findings of the study have been published in the Archives of Ophthalmology and the Annals of the New York Academy of Sciences.
The screening of the first patient in Phase 2 trial with RegeneRx’s RGN-259 for Dry eye Syndrome is an important milestone. This is definitely very encouraging news. I hope, the study will witness significant progresses over the next few years.
- Clinical Trials (Medical Studies) of Myelodysplastic Syndrome (MDS) Treatments
- Learning from Taylor Lautner and my Dad about Restless Leg Syndrome!
- Should all patients with metabolic syndrome or elevated HgA1c take statins?
- PolyCystic Ovary Syndrome (PCOS)- List of Clinical Trials of New Treatments
- Ozzy Osbourne Fights Parkinson’s Disease (Parkin Syndrome) With His Music!